From:  Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma

Related drugs targeting FXR

FXR agonistsAliasMolecular formulaChemical structureR & D stageReferences
Obeticholic acid6-Ethyl-chenodeoxycholic-acid, OCAC26H44O4Approval to market[24, 25]
GW4064GW-4064C28H22Cl3NO4Preclinical[24, 25]
CilofexorCILO, GS-9674C32H33Cl3N4O8Phase III[24, 25]
TropifexorLJN-452, NVP-LJN452-NXAC29H25F4N3O5SPhase II[24, 25]
EDP-305EDP 305C36H58N2O5SPhase II[27]
LY-2562175NoneC28H27Cl2N3O4Phase II[24, 25]
Return to article view